MGC Pharmaceuticals has received ethics committee approval from two Israeli hospitals for a Phase III clinical trial of its anti-inflammatory treatment CimetrA (formerly ArtemiC) on Covid-19 patients.
The company expects the trial to start in early April with interim results due out in June and final results expected around October.
Following hot on the heels of its acquisition of Canadian psychedelics company Halucenex Life Sciences, Creso Pharma is preparing to apply for a dual listing on the US OTCQB exchange.
Expected to be live within the next seven weeks, Creso said the listing will provide it with access to one of the world’s largest investment markets at nominal cost.
UPDATE (March 25, 2021): Creso has entered a trading halt on the ASX while it considers, plans and executes a capital raising. The halt will remain in place until the start of trading on Friday, March 26, or when an announcement is released to the market, whichever occurs soonest.
UPDATE (March 29, 2021): Creso announced on Friday (March 26, 2021) that it has secured firm commitments from institutional, professional, and sophisticated investors to raise up to A$18 million before costs by issuing approximately 94.7 million new fully paid ordinary shares. According to the Australian Financial Review, the placement was initially meant for $10 million but grew to $18 million ‘on the back of strong demand’.
Roots Sustainable Agricultural Technologies
Roots Sustainable Agricultural Technologies is eyeing US expansion after completing a survey of global suppliers and pricing for hemp-based protein products in collaboration with Czech company Hempoint.
Roots will use the survey findings to progress several initiatives, including the launch of hemp-based meat replacement products and the establishment of a US hemp-based food venture.